Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Identifieur interne : 000207 ( PubMed/Checkpoint ); précédent : 000206; suivant : 000208Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Auteurs : Annalisa Pinna [Italie] ; Wai Kin D. Ko [Royaume-Uni] ; Giulia Costa [Italie] ; Elisabetta Tronci [Italie] ; Camino Fidalgo [Italie] ; Nicola Simola [Italie] ; Qin Li [Royaume-Uni] ; Mojgan Aghazadeh Tabrizi [Italie] ; Erwan Bezard [Royaume-Uni] ; Manolo Carta [Italie] ; Micaela Morelli [Italie]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2016.
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacology), Behavior, Animal (drug effects), Disease Models, Animal, Drug Therapy, Combination, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (prevention & control), Female, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (pharmacology), Macaca fascicularis, Male, Parkinson Disease (drug therapy), Piperazines (administration & dosage), Piperazines (pharmacology), Pyrimidines (administration & dosage), Pyrimidines (pharmacology), Rats, Rats, Sprague-Dawley, Serotonin Receptor Agonists (administration & dosage), Serotonin Receptor Agonists (pharmacology), Triazoles (administration & dosage), Triazoles (pharmacology).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa, Piperazines, Pyrimidines, Serotonin Receptor Agonists, Triazoles.
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , pharmacology : Antiparkinson Agents, Levodopa, Piperazines, Pyrimidines, Serotonin Receptor Agonists, Triazoles.
- drug effects : Behavior, Animal.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- prevention & control : Dyskinesia, Drug-Induced.
- Animals, Disease Models, Animal, Drug Therapy, Combination, Female, Macaca fascicularis, Male, Rats, Rats, Sprague-Dawley.
Abstract
The serotonin 5-HT1A/1B receptor agonist eltoprazine suppressed dyskinetic-like behavior in animal models of Parkinson's disease (PD) but simultaneously reduced levodopa (l-dopa)-induced motility. Moreover, adenosine A2A receptor antagonists, such as preladenant, significantly increased l-dopa efficacy in PD without exacerbating dyskinetic-like behavior.
DOI: 10.1002/mds.26475
PubMed: 26871939
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26871939Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.</title><author><name sortKey="Pinna, Annalisa" sort="Pinna, Annalisa" uniqKey="Pinna A" first="Annalisa" last="Pinna">Annalisa Pinna</name><affiliation wicri:level="1"><nlm:affiliation>National Research Council of Italy, Neuroscience Institute, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>National Research Council of Italy, Neuroscience Institute, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Ko, Wai Kin D" sort="Ko, Wai Kin D" uniqKey="Ko W" first="Wai Kin D" last="Ko">Wai Kin D. Ko</name><affiliation wicri:level="3"><nlm:affiliation>Motac Neuroscience Ltd, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Costa, Giulia" sort="Costa, Giulia" uniqKey="Costa G" first="Giulia" last="Costa">Giulia Costa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, section of Neuropsychopharmacology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical Sciences, section of Neuropsychopharmacology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Tronci, Elisabetta" sort="Tronci, Elisabetta" uniqKey="Tronci E" first="Elisabetta" last="Tronci">Elisabetta Tronci</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Fidalgo, Camino" sort="Fidalgo, Camino" uniqKey="Fidalgo C" first="Camino" last="Fidalgo">Camino Fidalgo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Simola, Nicola" sort="Simola, Nicola" uniqKey="Simola N" first="Nicola" last="Simola">Nicola Simola</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, section of Neuropsychopharmacology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical Sciences, section of Neuropsychopharmacology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Li, Qin" sort="Li, Qin" uniqKey="Li Q" first="Qin" last="Li">Qin Li</name><affiliation wicri:level="3"><nlm:affiliation>Motac Neuroscience Ltd, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Tabrizi, Mojgan Aghazadeh" sort="Tabrizi, Mojgan Aghazadeh" uniqKey="Tabrizi M" first="Mojgan Aghazadeh" last="Tabrizi">Mojgan Aghazadeh Tabrizi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><affiliation wicri:level="3"><nlm:affiliation>Motac Neuroscience Ltd, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Carta, Manolo" sort="Carta, Manolo" uniqKey="Carta M" first="Manolo" last="Carta">Manolo Carta</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Morelli, Micaela" sort="Morelli, Micaela" uniqKey="Morelli M" first="Micaela" last="Morelli">Micaela Morelli</name><affiliation wicri:level="1"><nlm:affiliation>National Research Council of Italy, Neuroscience Institute, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>National Research Council of Italy, Neuroscience Institute, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26871939</idno><idno type="pmid">26871939</idno><idno type="doi">10.1002/mds.26475</idno><idno type="wicri:Area/PubMed/Corpus">000170</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000170</idno><idno type="wicri:Area/PubMed/Curation">000170</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000170</idno><idno type="wicri:Area/PubMed/Checkpoint">000170</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000170</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.</title><author><name sortKey="Pinna, Annalisa" sort="Pinna, Annalisa" uniqKey="Pinna A" first="Annalisa" last="Pinna">Annalisa Pinna</name><affiliation wicri:level="1"><nlm:affiliation>National Research Council of Italy, Neuroscience Institute, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>National Research Council of Italy, Neuroscience Institute, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Ko, Wai Kin D" sort="Ko, Wai Kin D" uniqKey="Ko W" first="Wai Kin D" last="Ko">Wai Kin D. Ko</name><affiliation wicri:level="3"><nlm:affiliation>Motac Neuroscience Ltd, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Costa, Giulia" sort="Costa, Giulia" uniqKey="Costa G" first="Giulia" last="Costa">Giulia Costa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, section of Neuropsychopharmacology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical Sciences, section of Neuropsychopharmacology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Tronci, Elisabetta" sort="Tronci, Elisabetta" uniqKey="Tronci E" first="Elisabetta" last="Tronci">Elisabetta Tronci</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Fidalgo, Camino" sort="Fidalgo, Camino" uniqKey="Fidalgo C" first="Camino" last="Fidalgo">Camino Fidalgo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Simola, Nicola" sort="Simola, Nicola" uniqKey="Simola N" first="Nicola" last="Simola">Nicola Simola</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, section of Neuropsychopharmacology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical Sciences, section of Neuropsychopharmacology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Li, Qin" sort="Li, Qin" uniqKey="Li Q" first="Qin" last="Li">Qin Li</name><affiliation wicri:level="3"><nlm:affiliation>Motac Neuroscience Ltd, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Tabrizi, Mojgan Aghazadeh" sort="Tabrizi, Mojgan Aghazadeh" uniqKey="Tabrizi M" first="Mojgan Aghazadeh" last="Tabrizi">Mojgan Aghazadeh Tabrizi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><affiliation wicri:level="3"><nlm:affiliation>Motac Neuroscience Ltd, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Carta, Manolo" sort="Carta, Manolo" uniqKey="Carta M" first="Manolo" last="Carta">Manolo Carta</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Morelli, Micaela" sort="Morelli, Micaela" uniqKey="Morelli M" first="Micaela" last="Morelli">Micaela Morelli</name><affiliation wicri:level="1"><nlm:affiliation>National Research Council of Italy, Neuroscience Institute, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>National Research Council of Italy, Neuroscience Institute, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (pharmacology)</term><term>Behavior, Animal (drug effects)</term><term>Disease Models, Animal</term><term>Drug Therapy, Combination</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Dyskinesia, Drug-Induced (prevention & control)</term><term>Female</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Levodopa (pharmacology)</term><term>Macaca fascicularis</term><term>Male</term><term>Parkinson Disease (drug therapy)</term><term>Piperazines (administration & dosage)</term><term>Piperazines (pharmacology)</term><term>Pyrimidines (administration & dosage)</term><term>Pyrimidines (pharmacology)</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Serotonin Receptor Agonists (administration & dosage)</term><term>Serotonin Receptor Agonists (pharmacology)</term><term>Triazoles (administration & dosage)</term><term>Triazoles (pharmacology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term><term>Piperazines</term><term>Pyrimidines</term><term>Serotonin Receptor Agonists</term><term>Triazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term><term>Piperazines</term><term>Pyrimidines</term><term>Serotonin Receptor Agonists</term><term>Triazoles</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Drug Therapy, Combination</term><term>Female</term><term>Macaca fascicularis</term><term>Male</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The serotonin 5-HT1A/1B receptor agonist eltoprazine suppressed dyskinetic-like behavior in animal models of Parkinson's disease (PD) but simultaneously reduced levodopa (l-dopa)-induced motility. Moreover, adenosine A2A receptor antagonists, such as preladenant, significantly increased l-dopa efficacy in PD without exacerbating dyskinetic-like behavior.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26871939</PMID><DateCreated><Year>2016</Year><Month>04</Month><Day>15</Day></DateCreated><DateCompleted><Year>2017</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>501-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26475</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The serotonin 5-HT1A/1B receptor agonist eltoprazine suppressed dyskinetic-like behavior in animal models of Parkinson's disease (PD) but simultaneously reduced levodopa (l-dopa)-induced motility. Moreover, adenosine A2A receptor antagonists, such as preladenant, significantly increased l-dopa efficacy in PD without exacerbating dyskinetic-like behavior.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We evaluated whether a combination of eltoprazine and preladenant may prevent or suppress l-dopa-induced dyskinesia, without impairing l-dopa's efficacy in relieving motor signs, in 2 PD models: unilateral 6-hydroxydopamine-lesioned rats and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Rotational behavior and abnormal involuntary movements, or disability and l-dopa-induced dyskinesia were evaluated in 6-hydroxydopamine-lesioned rats and MPTP-treated monkeys, respectively. Moreover, in the rodent striatum, induction of immediate-early gene zif-268, an index of long-term changes, was correlated with dyskinesia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 6-hydroxydopamine-lesioned rats, combined administration of l-dopa (4 mg/kg) plus eltoprazine (0.6 mg/kg) plus preladenant (0.3 mg/kg) significantly prevented or reduced dyskinetic-like behavior without impairing motor activity. Zif-268 was increased in the striatum of rats treated with l-dopa and l-dopa plus preladenant compared with vehicle. In contrast, rats treated with eltoprazine (with or without preladenant) had lower zif-268 activation after chronic treatment in both the dyskinetic and l-dopa-non-primed groups. Moreover, acute l-dopa plus eltoprazine plus preladenant prevented worsening of motor performance (adjusting step) and sensorimotor integration deficit. Similar results were obtained in MPTP-treated monkeys, where a combination of preladenant with eltoprazine was found to counteract dyskinesia and maintain the full therapeutic effects of a low dose of l-dopa.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggest a promising nondopaminergic pharmacological strategy for the treatment of dyskinesia in PD. © 2016 International Parkinson and Movement Disorder Society.</AbstractText><CopyrightInformation>© 2016 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinna</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Research Council of Italy, Neuroscience Institute, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Wai Kin D</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Motac Neuroscience Ltd, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, section of Neuropsychopharmacology, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tronci</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fidalgo</LastName><ForeName>Camino</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simola</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, section of Neuropsychopharmacology, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Motac Neuroscience Ltd, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabrizi</LastName><ForeName>Mojgan Aghazadeh</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezard</LastName><ForeName>Erwan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Motac Neuroscience Ltd, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carta</LastName><ForeName>Manolo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, section of Physiology, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morelli</LastName><ForeName>Micaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Research Council of Italy, Neuroscience Institute, Cagliari, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, section of Neuropsychopharmacology, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017366">Serotonin Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014230">Triazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>510M006KO6</RegistryNumber><NameOfSubstance UI="C063828">eltoprazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>950O97NUPO</RegistryNumber><NameOfSubstance UI="C539997">2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017366" MajorTopicYN="N">Serotonin Receptor Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adenosine A2A receptor antagonist</Keyword><Keyword MajorTopicYN="N">dyskinesia</Keyword><Keyword MajorTopicYN="N">non-human primate</Keyword><Keyword MajorTopicYN="N">rodent</Keyword><Keyword MajorTopicYN="N">serotonin 5-HT1A/1B receptor agonist</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>09</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26871939</ArticleId><ArticleId IdType="doi">10.1002/mds.26475</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Manchester</li></region><settlement><li>Manchester</li></settlement></list><tree><country name="Italie"><noRegion><name sortKey="Pinna, Annalisa" sort="Pinna, Annalisa" uniqKey="Pinna A" first="Annalisa" last="Pinna">Annalisa Pinna</name></noRegion><name sortKey="Carta, Manolo" sort="Carta, Manolo" uniqKey="Carta M" first="Manolo" last="Carta">Manolo Carta</name><name sortKey="Costa, Giulia" sort="Costa, Giulia" uniqKey="Costa G" first="Giulia" last="Costa">Giulia Costa</name><name sortKey="Fidalgo, Camino" sort="Fidalgo, Camino" uniqKey="Fidalgo C" first="Camino" last="Fidalgo">Camino Fidalgo</name><name sortKey="Morelli, Micaela" sort="Morelli, Micaela" uniqKey="Morelli M" first="Micaela" last="Morelli">Micaela Morelli</name><name sortKey="Simola, Nicola" sort="Simola, Nicola" uniqKey="Simola N" first="Nicola" last="Simola">Nicola Simola</name><name sortKey="Tabrizi, Mojgan Aghazadeh" sort="Tabrizi, Mojgan Aghazadeh" uniqKey="Tabrizi M" first="Mojgan Aghazadeh" last="Tabrizi">Mojgan Aghazadeh Tabrizi</name><name sortKey="Tronci, Elisabetta" sort="Tronci, Elisabetta" uniqKey="Tronci E" first="Elisabetta" last="Tronci">Elisabetta Tronci</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Ko, Wai Kin D" sort="Ko, Wai Kin D" uniqKey="Ko W" first="Wai Kin D" last="Ko">Wai Kin D. Ko</name></region><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><name sortKey="Li, Qin" sort="Li, Qin" uniqKey="Li Q" first="Qin" last="Li">Qin Li</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000207 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000207 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26871939
|texte= Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26871939" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |